1092523-21-1

Basic information

• Product Name: 6-Chloro-2-ethylaMinonicotinic Acid
• Synonyms: 6-Chloro-2-ethylaMinonicotinic Acid
• CAS NO: 1092523-21-1
• Molecular Formula: C₈H₉ClN₂O₂
• Molecular Weight: 200.62226
• Product Categories: Amines, Heterocycles, Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1092523-21-1.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 384.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.401±0.06 g/cm3(Predicted)
• Solubility: Acetone, Ethyl Acetate
• PKA: 3.28±0.36(Predicted)
• CAS DataBase Reference: 6-Chloro-2-ethylaMinonicotinic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-2-ethylaMinonicotinic Acid(1092523-21-1)
• EPA Substance Registry System: 6-Chloro-2-ethylaMinonicotinic Acid(1092523-21-1)

Safety Data

• Hazardous Substances Data: 1092523-21-1(Hazardous Substances Data)

Usage

Description

6-Chloro-2-ethylaminonicotinic Acid is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals. It is characterized by its unique chemical structure, which includes a chlorine atom at the 6th position and an ethylamine group at the 2nd position of the nicotinic acid backbone. 6-Chloro-2-ethylaMinonicotinic Acid plays a significant role in the development of targeted therapies for specific medical conditions.

Uses

Used in Pharmaceutical Industry:
6-Chloro-2-ethylaminonicotinic Acid is used as an intermediate in the synthesis of SAR131675 (S139510) for its potent and selective inhibition of VEGFR-3. This makes it a valuable compound in the development of treatments for conditions related to abnormal blood vessel growth, such as certain types of cancer and vascular disorders.
In the development of targeted therapies, 6-Chloro-2-ethylaminonicotinic Acid is used as a building block to create molecules that can specifically target and inhibit the activity of VEGFR-3. This targeted approach can potentially lead to more effective treatments with fewer side effects compared to non-targeted therapies.
Additionally, the compound may have potential applications in other areas of pharmaceutical research, such as the development of new drugs for other diseases or the improvement of existing drug formulations. However, further research and development would be required to explore these possibilities.

Upstream product

• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 75-04-7 ethylamine 

Downstream Products

• 1308917-77-2 (4-{7-Amino-8-ethyl-5-oxo-6-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-5,8-dihydro-[1,8]naphthyridin-2-yl}-phenyl)-acetic acid 
• 1308917-80-7 2-{4-[7-amino-8-ethyl-5-oxo-6-(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}-N-[(4-cyclopropylmorpholin-3-yl)methyl]acetamide 
• 1308917-78-3 C₂₉H₃₇N₅O₄Si 
• 1314069-32-3 2-amino-7-(4-{[(2,3-dichlorophenyl)sulfonyl]amino}-3-fluorophenyl)-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1092523-22-2 6-chloro-2-(ethylamino)pyridine-3-carbonyl fluoride 
• 1412454-13-7 2-amino-7-(3-chloro-4-hydroxy-phenyl)-1-ethyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-1H-[1,8]naphthyridin-4-one 
• 1412453-78-1 2-Amino-1-ethyl-7-[3-(2-fluorophenyl)-3-hydroxybut-1-yn-1-yl]-3-(1H-imidazol-2-yl)-1,8-naphthyridin-4(1H)-one 
• 1412453-77-0 2-amino-7-(3-chloro-4-hydroxy-phenyl)-1-ethyl-3-(1H-imidazol-2-yl)-1H-[1,8]naphthyridin-4-one 
• 1246494-92-7 6-(4-{[({6-[(bis-tert-butoxycarbonyl)amino]pyridin-3-yl}methyl)carbamoyl]amino}-3-fluorophenyl)-2-(ethylamino)nicotinic acid 
• 1246495-00-0 6-{4-[(E)-3-(pyridin-3-yl)acryloylamino]-3-fluorophenyl}-2-ethylamino-N-[2-(piperidin-1-yl)ethyl]nicotinamide 
• 1246494-52-9 6-{4-[3-(6-aminopyridin-3-ylmethyl)ureido]-3-fluorophenyl}-2-ethylamino-N-(2-hydroxyethyl)nicotinamide 
• 1363568-77-7 di(tert-butyl) [5-({[(4-{6-(ethylamino)-5-[(2-hydroxyethyl)carbamoyl]pyridin-2-yl}-2-fluorophenyl)carbamoyl]amino}methyl)pyridin-2-yl]imidodicarbonate 
• 1246494-87-0 6-(4-amino-3-fluorophenyl)-2-ethylamino-N-[2-(piperidin-1-yl)ethyl]nicotinamide 
• 1246494-45-0 6-{4-[3-(6-aminopyridin-3-ylmethyl)ureido]-3-fluorophenyl}-2-ethylamino-N-[2-(piperidin-1-yl)ethyl]nicotinamide 

Relevant articles and documents

USE OF VEGFR-3 INHIBITORS FOR TREATING HEPATOCELLULAR CARCINOMA

This invention is related to the use of inhibitors of vascular endothelial growth factor receptor 3 for treating hepatocellular carcinoma.

ARYLSULFONAMIDE PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION OF SAME, AND THERAPEUTIC USE THEREOF

The invention relates to pyridine-pyridinone derivatives general formula (I): in which R1, R2, R3, R4, n, n′, V, W, Y, Z, Ar are as defined in the description, and to their methods of preparation and their therapeutic applications.

NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS

The present invention relates to nicotinamide derivatives of formula (I), to compositions containing same, and to the therapeutic use thereof, in particular as anticancer drugs. The invention also relates to the method for preparing said compounds, as wel